Iovance Biotherapeutics, Inc. IOVA Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s free cash flow yield?
- Iovance Biotherapeutics, Inc. (IOVA) reported free cash flow yield of -21.1% in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s free cash flow yield changed year-over-year?
- Iovance Biotherapeutics, Inc.'s free cash flow yield increased by 33.7% year-over-year, from -31.8% to -21.1%.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s free cash flow yield?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s free cash flow yield has grown at a 53.1% compound annual growth rate (CAGR), from -3.7% to -31%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.